C
Carlijn M. van der Aalst
Researcher at Erasmus University Rotterdam
Publications - 52
Citations - 5038
Carlijn M. van der Aalst is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Lung cancer screening & Lung cancer. The author has an hindex of 23, co-authored 48 publications receiving 3449 citations. Previous affiliations of Carlijn M. van der Aalst include Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial
Harry J. de Koning,Carlijn M. van der Aalst,Pim A. de Jong,Ernst Th. Scholten,Kristiaan Nackaerts,Marjolein A Heuvelmans,Jan-Willem J. Lammers,Carla Weenink,Uraujh Yousaf-Khan,Nanda Horeweg,Susan van 't Westeinde,Mathias Prokop,Willem P.Th.M. Mali,Firdaus A. A. Mohamed Hoesein,Peter M. A. van Ooijen,Joachim G.J.V. Aerts,Michael A. den Bakker,Erik Thunnissen,Johny Verschakelen,Rozemarijn Vliegenthart,Joan Walter,Kevin ten Haaf,Harry J.M. Groen,Matthijs Oudkerk +23 more
TL;DR: In this trial involving high-risk persons, lung-cancer mortality was significantly lower among those who underwent volume CT screening than among thoseWho underwent no screening.
Journal ArticleDOI
Management of lung nodules detected by volume CT scanning
Rob J. van Klaveren,Matthijs Oudkerk,Mathias Prokop,Ernst T. Scholten,Kristiaan Nackaerts,René M. Vernhout,Carola A. van Iersel,Karien A. M. van den Bergh,Susan van 't Westeinde,Carlijn M. van der Aalst,Erik Thunnissen,Dong Ming Xu,Ying Wang,Yingru Zhao,Hester A. Gietema,Bartjan de Hoop,Harry J.M. Groen,Geertruida H. de Bock,Peter M. A. van Ooijen,Carla Weenink,Johny Verschakelen,Jan-Willem J. Lammers,Wim Timens,Dik Willebrand,Aryan Vink,Willem P.Th.M. Mali,Harry J. de Koning +26 more
TL;DR: Among subjects at high risk for lung cancer who were screened in three rounds of CT scanning and in whom noncalcified pulmonary nodules were evaluated according to volume and volume-doubling time, the chances of finding lung cancer 1 and 2 years after a negative first-round test were 1 in 1000 and 3 in 1000, respectively.
Journal ArticleDOI
Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening
Nanda Horeweg,Joost van Rosmalen,Marjolein A Heuvelmans,Carlijn M. van der Aalst,Rozemarijn Vliegenthart,Ernst T. Scholten,Kevin ten Haaf,Kristiaan Nackaerts,Jan-Willem J. Lammers,Carla Weenink,Harry J.M. Groen,Peter M. A. van Ooijen,Pim A. de Jong,Geertruida H. de Bock,Willem P.Th.M. Mali,Harry J. de Koning,Matthijs Oudkerk +16 more
TL;DR: This prespecified analysis quantifies how nodule diameter, volume, and volume doubling time affect the probability of developing lung cancer within 2 years of a CT scan, and proposes and evaluates thresholds for management protocols.
Journal ArticleDOI
Detection of lung cancer through low-dose CT screening (NELSON): A prespecified analysis of screening test performance and interval cancers
Nanda Horeweg,Ernst T. Scholten,Pim A. de Jong,Carlijn M. van der Aalst,Carla Weenink,Jan-Willem J. Lammers,Kristiaan Nackaerts,Rozemarijn Vliegenthart,Kevin ten Haaf,Uraujh Yousaf-Khan,Marjolein A Heuvelmans,Erik Thunnissen,Matthijs Oudkerk,Willem P.Th.M. Mali,Harry J. de Koning +14 more
TL;DR: Lung cancer screening in the NELSON trial yielded high specificity and sensitivity, with only a small number of interval cancers, which could be used to improve screening algorithms.
Journal ArticleDOI
Characteristics of Lung Cancers Detected by Computer Tomography Screening in the Randomized NELSON Trial
Nanda Horeweg,Carlijn M. van der Aalst,Erik Thunnissen,Kristiaan Nackaerts,Carla Weenink,Harry J.M. Groen,Jan-Willem J. Lammers,Joachim G.J.V. Aerts,Ernst T. Scholten,Joost van Rosmalen,Willem P.Th.M. Mali,Matthijs Oudkerk,Harry J. de Koning +12 more
TL;DR: Despite stringent criteria for a positive screening, an increasing length of screening interval, and few female participants, the screening strategy of the NELSON trial resulted in a favorable cancer stage distribution at diagnosis, which is essential for the effectiveness of this screening strategy.